Work

Phase 1b study of the novel first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-relapsed and refractory solid malignancies and dose escalation update.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.2574

Authors: Carolyn Muller, Marya F. Chaney, Justine Vanessa Cohen, Tina Garyantes, Jessica Jiyeong Lin, Patricia LoRusso, Alain C. Mita, Monica M. Mita, Christopher Natale, Marlana M. Orloff, Kyriakos P. Papadopoulos, Sapna Pradyuman Patel, Jordi Rodon Ahnert

Institutions: University of New Mexico, Merck & Co., Inc., Rahway, NJ, USA (United States), Massachusetts General Hospital, Harvard University, Yale University, Cedars-Sinai Medical Center, Thomas Jefferson University, South Texas Accelerated Research Therapeutics, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281730258

Cites:

Cited by: 17

Related to: 10